A detailed history of Dana Investment Advisors, Inc. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Dana Investment Advisors, Inc. holds 34,852 shares of DNLI stock, worth $748,969. This represents 0.03% of its overall portfolio holdings.

Number of Shares
34,852
Previous 34,269 1.7%
Holding current value
$748,969
Previous $795,000 27.67%
% of portfolio
0.03%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$20.96 - $31.05 $12,219 - $18,102
583 Added 1.7%
34,852 $1.02 Million
Q2 2024

Aug 13, 2024

BUY
$14.96 - $23.22 $82,474 - $128,011
5,513 Added 19.17%
34,269 $795,000
Q1 2024

May 15, 2024

BUY
$15.83 - $23.35 $74,385 - $109,721
4,699 Added 19.53%
28,756 $590,000
Q4 2023

Feb 07, 2024

SELL
$16.2 - $23.18 $9,266 - $13,258
-572 Reduced 2.32%
24,057 $516,000
Q3 2023

Nov 15, 2023

SELL
$20.63 - $30.17 $50,130 - $73,313
-2,430 Reduced 8.98%
24,629 $508,000
Q2 2023

Aug 15, 2023

BUY
$23.37 - $32.96 $6,076 - $8,569
260 Added 0.97%
27,059 $798,000
Q1 2023

May 15, 2023

BUY
$21.91 - $32.67 $36,874 - $54,983
1,683 Added 6.7%
26,799 $617,000
Q4 2022

Feb 13, 2023

BUY
$26.28 - $33.92 $124,015 - $160,068
4,719 Added 23.14%
25,116 $698,000
Q3 2022

Nov 15, 2022

BUY
$25.97 - $38.53 $183,010 - $271,520
7,047 Added 52.79%
20,397 $626,000
Q2 2022

Aug 15, 2022

BUY
$20.88 - $35.19 $42,887 - $72,280
2,054 Added 18.18%
13,350 $393,000
Q1 2022

May 12, 2022

BUY
$29.0 - $47.27 $48,082 - $78,373
1,658 Added 17.2%
11,296 $363,000
Q4 2021

Feb 09, 2022

BUY
$42.59 - $55.02 $13,884 - $17,936
326 Added 3.5%
9,638 $430,000
Q3 2021

Nov 12, 2021

BUY
$48.48 - $78.23 $451,445 - $728,477
9,312 New
9,312 $470,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Dana Investment Advisors, Inc. Portfolio

Follow Dana Investment Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dana Investment Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Dana Investment Advisors, Inc. with notifications on news.